Unveiling Patient Experiences in Testicular Cancer Clinical Trials
NCT05928377 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-07-03
Summary
Clinical research participation has historically been heavily biased toward specific demographics.
Several people will be invited to enroll in this study so that it may collect a variety of data about testicular cancer clinical study experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal.
People with testicular cancer who are invited to take part in medical research will benefit from the analysis of the data.
Conditions
- Testicular Cancer
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-07-31
- Primary Completion
- 2025-07-31
- Completion
- 2026-07-31
Countries
- United States
Study Locations
More Related Trials
-
Follow-up After Surgery for Testicular Cancer
NCT05670938 ·Status: RECRUITING
-
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT01718353 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT06800313 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02905318 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer
NCT01075308 ·Status: COMPLETED ·Phase: PHASE2
-
Shared Care Follow-up After Chemotherapy for Testicular Cancer
NCT01783145 ·Status: ACTIVE_NOT_RECRUITING
-
Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
NCT02286921 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06879041 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
NCT06890832 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm
NCT06940804 ·Status: WITHDRAWN ·Phase: PHASE2
-
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
NCT06470243 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
NCT02441517 ·Status: TERMINATED ·Phase: PHASE4
-
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
NCT01505868 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT05168618 ·Status: RECRUITING ·Phase: PHASE2
-
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
NCT02522715 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
NCT02598895 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06801236 ·Status: RECRUITING ·Phase: PHASE1
-
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
NCT05611307 ·Status: TERMINATED
-
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT02844582 ·Status: TERMINATED ·Phase: PHASE2
-
Testosterone Therapy in Castration Resistant Prostate Cancer
NCT03734653 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients
NCT02091531 ·Status: COMPLETED ·Phase: PHASE2
-
Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00006023 ·Status: COMPLETED ·Phase: PHASE2
-
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
NCT05011383 ·Status: RECRUITING ·Phase: PHASE2
-
Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00527124 ·Status: TERMINATED ·Phase: PHASE2